Compare INBK & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | INBK | IKT |
|---|---|---|
| Founded | 1999 | 2008 |
| Country | United States | United States |
| Employees | 355 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 226.9M | 220.5M |
| IPO Year | N/A | 2020 |
| Metric | INBK | IKT |
|---|---|---|
| Price | $26.52 | $2.04 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $23.25 | $5.00 |
| AVG Volume (30 Days) | 31.1K | ★ 887.2K |
| Earning Date | 04-30-2026 | 03-26-2026 |
| Dividend Yield | ★ 1.06% | N/A |
| EPS Growth | N/A | ★ 57.76 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $279.34 | N/A |
| Revenue Next Year | $12.97 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $17.05 | $1.33 |
| 52 Week High | $28.88 | $2.26 |
| Indicator | INBK | IKT |
|---|---|---|
| Relative Strength Index (RSI) | 50.18 | 66.00 |
| Support Level | $24.92 | $1.59 |
| Resistance Level | $26.47 | $2.13 |
| Average True Range (ATR) | 1.01 | 0.11 |
| MACD | -0.19 | 0.02 |
| Stochastic Oscillator | 25.81 | 73.53 |
First Internet Bancorp is a bank holding company. Through its subsidiaries, it provides commercial real estate (CRE) lending, including nationwide single tenant lease financing and commercial and industrial (C&I) lending, including business banking or treasury management services. The company offers its products and services through the internet and does not have any branches. With operations organized into a single segment called the Commercial Banking segment, it also provides retail banking services.
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.